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Trends in utilization and outcomes after autologous or allogeneic hematopoietic cell transplantation (HCT) for
Burkitt lymphoma were analyzed in 241 recipients reported to the Center for International Blood and Marrow
Transplant Research between 1985 and 2007. The autologous HCT cohort had a higher proportion of
chemotherapy-sensitive disease, peripheral blood grafts, and HCT in ﬁrst complete remission (CR1). The use
of autologous HCT has declined over time, with only 19% done after 2001. Overall survival at 5 years for the
autologous cohort was 83% for those in CR1 and 31% for those not in CR1. Corresponding progression-free
survival (PFS) was 78% and 27%, respectively. After allogeneic HCT, overall survival at 5 years was 53% and
20% for the CR1 and non-CR1 cohorts, whereas PFS was 50% and 19%, respectively. The most common cause of
death was progressive lymphoma. Allogeneic HCT performed in a higher-risk subset (per National Compre-
hensive Cancer Network guidelines) resulted in a 5-year PFS of 27%. Autologous HCT resulted in a 5-year PFS
of 44% in those undergoing transplantation in the second CR.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION monomorphic, medium-sized B cells with basophilic cyto-
Burkitt lymphoma (BL) is an aggressive but highly curable
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12.11.016plasm and numerous mitotic ﬁgures. Chromosomal trans-
location leading to over-expression ofMYC, a growth fraction
of nearly 100%, and a common predilection for extranodal
disease sites are consistent features [1,2]. Median age at
diagnosis of BL is 45 years, and 30% of patients are over the
age of 60 years [3]. Although three clinical variants of BL
(endemic, sporadic, and immunodeﬁciency-associated BL)
have been distinguished, sporadic BL accounts for 1% to 2% ofTransplantation.
Table 1
Characteristics of Recipients of Autologous, HLA-Identical Sibling, or Unrelated/Mismatched Related Donor HCT for BL
Autologous n (%) HLA-Identical
Sibling n (%)
Unrelated/Mismatched
Related n (%)
P Value
Number of patients 113 80 48
Age, y, median (range) 31 (5-76) 24 (3-55) 22 (2-54) <.001
Age at transplant .005
<10 y 6 (5) 10 (13) 10 (21)
10-19 y 26 (23) 22 (28) 12 (25)
20-29 y 21 (19) 21 (26) 10 (21)
30-39 y 20 (18) 15 (19) 8 (17)
40-49 y 14 (12) 7 (9) 6 (13)
50-59 y 12 (11) 5 (6) 2 (4)
60 y 14 (12) 0 0
Male gender 79 (70) 53 (66) 39 (81) .183
Karnofsky score at HCT < 90% 32 (28) 29 (36) 23 (48) .184
Interval from diagnosis to transplantation, mo, median (range) 7 (2-74) 6 (1-29) 9 (1-113) .002
Disease stage at diagnosis .076
I-II 34 (30) 14 (18) 19 (40)
III-IV 76 (67) 50 (63) 26 (54)
Unknown 3 (3) 16 (20) 3 (6)
Number of prior chemotherapy lines .032
1 26 (23) 9 (11) 4 (8)
2 42 (37) 23 (29) 17 (35)
3 or more 25 (22) 18 (23) 22 (46)
Missing 20 (18) 30 (38) 5 (10)
Rituxan before treatment 6 (5) 11 (14) 12 (25) .002
Methotrexate or cytarabine before HCT 46 (32) 28 (35) 33 (69) <.001
Reduced-intensity conditioning NA 10 (13) 4 (8) .556
Conditioning regimen details, allogeneic group NA .609
Cy þ TBI 52 (65) 32 (67)
Bu þ Cy 12 (15) 5 (10)
Cy þ etoposide based 6 (8) 1 (2)
Others (low-dose TBI, Bu, MEL) 10 (12) 10 (20)
Conditioning regimen, autologous group NA NA NA
TBI-based 30 (27)
BEAM and similar 62 (55)
CBV or similar 12 (11)
BuMEL/BuCy 6 (5)
Others 3 (3)
Extranodal involvement at diagnosis 80 (71) 40 (50) 35 (73) <.001
Marrow involvement at diagnosis 25 (22) 17 (21) 13 (27) .011
Central nervous system involvement at diagnosis 13 (12) 10 (13) 5 (10) .398
Disease status before transplantation .001
PIF sensitive 13 (12) 8 (9) 8 (17)
PIF resistant 5 (4) 3 (4) 4 (8)
CR1 48 (42) 27 (34) 3 (6)
REL sensitive 17 (15) 3 (4) 6 (13)
REL resistant 3 (3) 4 (5) 6 (13)
CR2 or beyond 19 (17) 23 (29) 16 (33)
Unknown 8 (7) 12 (15) 5 (10)
Chemotherapy-sensitivity at transplantation .011
Sensitive 97 (86) 62 (78) 34 (71)
Graft type <.001
Bone marrow 31 (27) 55 (69) 32 (67)
Peripheral blood 82 (73) 25 (31) 8 (17)
Cord blood 0 0 8 (17)
Year of HCT <.001
1985-1988 1 (1) 17 (21) 0
1989-1992 21 (19) 10 (13) 2 (4)
1993-1996 31 (27) 16 (20) 7 (15)
1997-2000 38 (34) 16 (20) 9 (19)
2001-2004 16 (14) 15 (19) 19 (40)
2005-2007 6 (5) 6 (8) 11 (23)
GVHD prophylaxis NA <.001
T cell depletion 13 (16) 5 (10)
FK506þMTXþ-other 4 (5) 16 (33)
CsAþMTXþ-other 41 (51) 27 (56)
Median follow-up of survivors, mo 79 (9-222) 56 (4-233) 50 (26-160)
NA indicates not applicable; PIF, primary induction failure; REL, relapse; Cy, cyclophosphamide; MTX, methotrexate; CsA, cyclosporine; FK506, tacrolimus; MEL,
Melphalan; BEAM, BCNU/Etoposide/AraC/Melphalan; CBV, Cyclophosphamide/BCNU/Etoposide; TBI, total body irradiation; Bu, busulfan.
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Europe. Higher-level evidence-based therapeutic recom-
mendations are lacking in adult BL because of its relative
rarity in adults, lack of randomized trials in adult BL [3], andthe variable pathological deﬁnitions used over time [4].
However, with modern chemotherapy regimens-cure rates
have increased, with 3-year survival rates varying between
50% and 90% [5,6]. According to National Comprehensive
Table 2
Outcomes after HCT for BL
Outcome Event Autologous
(n ¼ 113)
HLA-Identical Siblings
(n ¼ 80)
Unrelated/Mismatched
Related (n ¼ 48)
P Value
Probability (95% CI) Probability (95% CI) Probability (95% CI)
100-day mortality 4 (1-8) 20 (12-30) 19 (9-31) <.001
Acute GVHD at 100 days, grades II-IV NA 35 (25-46) 53 (39-67) .044
Acute GVHD at 100 days, grades III-IV NA 15 (8-24) 35 (23-49) .010
Chronic GVHD NA
at 1 y 17 (9-26) 16 (7-28) .873
at 3 y 18 (10-28) 16 (7-28) .734
at 5 y 18 (10-28) 16 (7-28) .734
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drogenase, fully resected stage 1 disease, or a single mass
<10 cm represents low-risk disease, and all other patients
have high-risk disease [7]. These guidelines recommend no
preferred standard approaches to those with disease
relapsing after modern induction regimens; these patients
represent the highest-risk subset.
In the 1980s and 1990s, patients with BLwere treated with
regimens used for other non-Hodgkin lymphoma subtypes
with inferior remission rates and survival. Due to these poor
results with conventional chemotherapy, hematopoietic cell
transplantation (HCT) was used in high-risk patients as
consolidation therapy inﬁrst complete remission (CR1)orafter
relapse, although very few published reports are available.
Introduction of contemporary intensive multiagent therapy
with central nervous systemprophylaxis had dramatic results,
with 2-year disease-free survival rates of 75% to 80% in pedi-
atric patients with advanced disease [8]. The use of such brief,
high-intensity regimens in adults in combination with the
anti-CD20 antibody rituximab has resulted in dramatic
improvement, with reported 3-year survival rates close to 90%
in someseries [6]. It is hard to evaluate the role of autologousor
allogeneic HCT in the era of modern effective chemotherapy
regimens for BL. We analyzed trends in utilization and
outcomesof autologousandallogeneicHCT forBLover thepast
2 decades and the current utilization of HCT in BL so that
indirect comparison can bemadewith current chemotherapy.
METHODS
Data Source
The Center for International Blood and Marrow Transplant Research is
a voluntary group of more than 500 transplantation centers worldwide.
Participating centers register basic information on all consecutive HCTs to
a statistical center at the Medical College of Wisconsin. Detailed demo-
graphic and clinical data are collected on a representative sample ofTable 3
Outcomes of Patients in CR1 versus Beyond CR1
Outcome Event Autologous
CR1 Non-CR1
n Probability (95% CI) n Probability (95% CI
NRM 48 57
at 1 y 2 (0-10) 9 (3-18)
at 5 y 4 (1-13) 12 (5-22)
Progression/relapse 48 57
at 1 y 13 (5-24) 51 (38-63)
at 5 y 18 (8-30) 61 (47-73)
PFS 48 57
at 1 y 85 (71-93) 40 (27-52)
at 5 y 78 (63-88) 27 (16-40)
OS 48 57
at 1 y 85 (72-93) 42 (29-54)
at 5 y 83 (69-91) 31 (19-44)registered patients using a weighted randomization scheme. Compliance is
monitored by onsite audits. Patients are followed longitudinally, with yearly
follow-up. Computerized checks for errors, physician reviews of submitted
data, and onsite audits of participating centers ensure the quality of data.
Patients
The study population included all persons with BL or Burkitt leukemia
receiving an HCT reported to the Center for International Blood and
Marrow Transplant Research between 1985 and 2007. Because of their shared
immunophenotypic and cytogenetic features, BL and Burkitt leukemia (previ-
ously known as L3 acute lymphoblastic leukemia in the Frenche
AmericaneBritish classiﬁcation system) were analyzed as a combined group,
as has been performed in most modern series [5,9]. Central pathology review
was not performed.HIV-positive patientswere included in the analysis (n¼ 4).
Study Endpoints
Outcomes studied included nonrelapse mortality (NRM), progression/
relapse, progression-free survival (PFS), and overall survival (OS). NRM was
deﬁned as death within 28 days post-transplantation or death without
lymphoma progression. Progression/relapse was deﬁned as progressive
lymphoma after HCT (28 days) or lymphoma recurrence after a CR. For PFS,
subjects were considered treatment failures at the time of lymphoma
progression or death from any cause. OS interval was deﬁned as time from
the date of transplantation to the date of death with patients censored at the
time of last contact. Other outcomes analyzed included acute and chronic
graft-versus-host disease (aGVHD and cGVHD) and cause of death. aGVHD
and cGVHD were deﬁned and graded using established criteria.
Disease status before HCTwas deﬁned as follows. The primary induction
failure cohort was deﬁned as patients who never achieved CR (but could
have partial remission or stable or progressive disease on treatment).
Chemosensitive relapse was deﬁned as relapse with a partial response to
therapy (50% reduction in bidimensional diameter of all disease sites with
no new sites of disease). Chemoresistant relapse was deﬁned as relapsed
disease with a partial response to salvage therapy (<50% reduction in
diameter of all disease sites or development of new disease sites).
Statistical Analysis
Patient-, disease-, and transplantation-related variables and outcomes
were described in three cohorts: recipients of (1) autologous HCT or (2)
allogeneic HCT from matched sibling or from (3) unrelated/mismatched
related donors. Univariate probabilities of developing aGVHD and cGVHD,Allogeneic P Value
CR1 Non-CR1
) n Probability (95% CI) n Probability (95% CI)
30 80
23 (10-39) 27 (17-37) <.001
23 (10-39) 30 (20-40) <.001
30 80
24 (10-39) 51 (40-62) <.001
27 (13-44) 51 (40-62) <.001
30 80
53 (34-69) 22 (14-32) <.001
50 (30-66) 19 (11-29) <.001
30 81
53 (34-69) 23 (14-33) <.001
53 (34-69) 20 (12-30) <.001
Table 4
Outcomes of Patients in CR1 versus a Later Complete Remission (CR  2) versus Those Not in CR
Outcome Event Autologous Allogeneic P Value*
CR1 CR  2 Non-CR CR1 CR  2 Non-CR
n Probability
(95% CI)
n Probability
(95% CI)
n Probability
(95% CI)
n Probability
(95% CI)
n Probability
(95% CI)
n Probability
(95% CI)
Progression/relapse 48 19 38 30 39 41
at 1 y 13 (5-24) 44 (21-65) 55 (38-69) 24 (10-39) 49 (32-63) 54 (37-67) <.001
at 5 y 18 (8-30) 50 (26-70) 67 (49-79) 27 (13-44) 49 (32-63) 54 (37-67) <.001
PFS 48 19 38 30 39 41
at 1 y 85 (71-93) 50 (26-70) 34 (20-49) 53 (34-69) 30 (17-45) 14 (6-27) <.001
at 5 y 78 (63-88) 44 (21-65) 19 (9-34) 50 (30-66) 27 (15-42) 11 (4-24) <.001
OS 48 19 38 30 39 42
at 1 y 85 (72-93) 53 (29-72) 37 (22-52) 53 (34-69) 31 (17-45) 16 (6-28) <.001
at 5 y 83 (69-91) 53 (29-72) 22 (10-36) 53 (34-69) 28 (15-43) 12 (4-25) <.001
* Probabilities of treatment-related mortality and progression/relapse were calculated using the cumulative incidence estimate. PFS and OS were calculated
using the Kaplan-Meier product limit estimate.
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dence curves to accommodate competing risks. Probabilities of OS and PFS
were calculated using Kaplan-Meier estimator [10]. Conﬁdence intervals
(CIs) were calculated with a log transformation. Multivariate analyses were
not performed because of the imbalance in baseline characteristics of the
cohorts and the changes in BL management over the period studied.RESULTS
Patient-, Disease-, and Transplantation-Related Variables
Between 1985 and 2007, 249 patients received HCT for BL.
Threepatientswereexcluded fromanalysis due to inadequate
data collection, and ﬁve syngeneic twin transplantation
recipients were excluded. Of the 241 patients, 113 patients
received an autologous HCT, and 128 received an allogeneic
HCT. Completeness of follow-up (the ratio of the sum of the
observed follow-up time to the sumof the potential follow-up
time) for all subjects was 86% for both cohorts.
Table 1 describes subject-, disease-, and transplantation-
related variables of three cohorts analyzed: 113 autologous
HCT recipients, 80 HLA-identical sibling HCT recipients, and
48 unrelated or mismatched related donor graft recipients
(including 8 cord blood graft recipients). The autologous
cohort was older compared with the HLA-identical sibling
and unrelated/mismatched related cohorts (P < .001). Most
patients had a pretransplantation Karnofsky/Lansky perfor-
mance score of 90 or higher. Median time from diagnosis to
transplantation was 7 months (range, 2 to 74 months) in the
autologous cohort, 6 months (range, 1 to 29 months) in HLA-
identical sibling, and 9 months (range, 1 to 113 months) in
the unrelated/mismatched related cohort.Figure 1. Cumulative incidence of relapse after autologous and allogeneic
transplantation for BL by disease status.Most patients across cohorts had stage III or IV BL at diag-
nosis. The autologousHCTcohort tended to have fewer lines of
pre-HCT chemotherapy and more recipients underwent
transplantation in CR1. Central nervous system involvement
was similar across cohorts. Extranodal involvement at diag-
nosis was 71% in the autologous, 50% in the HLA-identical
sibling, and 73% in the unrelated/mismatched related
cohorts, respectively.At the timeofHCT, 42%of theautologous,
34% of the HLA-identical sibling, and 6% of the unrelated/
mismatched related cohorts were in CR1. The proportion of
patients with sensitivity to chemotherapy at HCT was 86% in
theautologous, 78% in thematched sibling allogeneic, and71%
in the unrelated/mismatched related cohorts.
The most common (55%) conditioning regimen before
autologous HCTwas BEAM (BCNU, etoposide, cytarabine, and
melphalan). There was limited use of reduced-intensity
conditioning (10%) before allogeneic HCT. Among myeloa-
blative regimens, cyclophosphamide and total body irradia-
tion and busulfan-cyclophosphamide accounted for >75%.
A substantial decline occurred in the numbers of autologous
HCT performed in recent years, with only 19% performed
after 2000. Similarly, there was increasing use of nonsibling
donor allografts in recent years (63% after 2000).Outcomes
Outcomes after HCT are summarized in Tables 2, 3, and 4.Nonrelapse Mortality
Day-100 mortality rates were 4% for the autologous
cohort, 20% for the HLA-identical sibling cohort, and 19% forFigure 2. Probability of OS and PFS after autologous transplantation for BL by
disease status.
Figure 3. Probability of OS and PFS after allogeneic transplantation for BL by
disease status.
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Cumulative incidence estimates of NRM at 5 years were 8%
(95% CI, 3 to 14) in the autologous cohort, 28% (95% CI, 19 to
38) in the HLA-identical sibling cohort, and 30% (95% CI, 18 to
44) in the unrelated/mismatched related cohort (P < .001).
For those receiving autologous HCT in CR1, the 5-year NRM
was 4% (95% CI, 1 to 13) versus 12% (95% CI, 5 to 22) for those
not in CR1 (P < .001; Table 3). Similar comparison in the
allogeneic cohort indicated a 5-year NRM of 23% (95% CI, 10
to 39) for those in CR1 versus 30% (95% CI, 20 to 40) for those
not in CR1 (P < .001).
Progression/Relapse
The 1-, 3-, and 5-year probability of progression were
similar in all cohorts; at 5 years, it was 44% (95% CI, 35 to 53)
in the autologous cohort, 42% (95% CI, 31 to 53) in the HLA-
identical sibling cohort, and 48% (95% CI, 34 to 62;
P ¼ .811) in the unrelated/mismatched related cohort. For
autologous HCT recipients treated in CR1 versus those
beyond CR1, the the progression rate was 18% (95% CI, 8 to
30) and 61% (95% CI, 47 to 73), respectively. For allogeneic
recipients, the progression risk at 5 years was 27% (95% CI, 13
to 44) for those in CR1 versus 51% (95% CI, 40 to 62; P < .001)
in recipients beyond CR1. Patients in later CR (CR  2)
receiving autologous or allogeneic HCT had a higher inci-
dence of lymphoma progression at 5 years (50% and 49%,
respectively) compared with those who underwent trans-
plantation in CR1 (P< .001; Table 4; Fig 1). For those not in CRFigure 4. Probability of OS and PFS aat HCT, the incidence of lymphoma progression at 5 years
was 67% for autologous and 54% for allogeneic cohorts.
Progression-Free Survival
The 1-, 3-, and 5-year PFS estimates for those receiving
autologous HCT were 60% (95% CI, 51 to 69), 53% (95% CI, 44
to 62), and 48% (95% CI, 39 to 58), respectively. Similar 1-, 3-,
and 5-year PFS estimates for the HLA-identical sibling cohort
were 33% (95% CI, 23 to 44), 31% (95% CI, 22 to 42), and 30%
(95% CI, 20 to 41), respectively. In the unrelated/mismatched
related cohort, 1-, 3-, and 5-year PFS estimates were 24%
(95% CI, 13 to 38), 22% (95% CI, 12 to 35), and 22% (95% CI, 12
to 35), respectively (P < .001).
The 5-year probability of PFS for recipients in CR1
receiving autologous HCT was 78% (95% CI, 63 to 88) versus
27% (95% CI, 16 to 40) in recipients beyond CR1. For recipients
of allogeneic HCT, 5-year PFS was 50% (95% CI, 30 to 66) for
those in CR1 versus 19% (95% CI, 11 to 29) in those not in CR1
(P < .001). Patients in a second or subsequent CR receiving
autologous or allogeneic HCT had inferior 5-year PFS, at 44%
(95% CI, 21 to 65) and 27%, (95% CI, 15 to 42), respectively
(Table 4). PFS at 5 years for those not in CR at HCT was 19%
(95% CI, 9 to 34) for autologous and 11% (95% CI, 4 to 24) for
allogeneic HCT cohorts (P < .001).
Survival Rates
OS rates at 1, 3, and 5 years for those receiving autologous
HCT were 62% (95% CI, 53 to 71), 57% (95% CI, 48 to 66), and
54% (95% CI, 44 to 63), respectively. OS rates at 1, 3, and 5
years for the HLA-identical sibling cohort were 33% (95% CI,
23 to 44), 31% (95% CI, 22 to 43), and 32% (95% CI, 22 to 43),
respectively. In the unrelated/mismatched related cohort, 1-,
3-, and 5-year OS rates were 25% (95% CI, 14 to 38), 23% (95%
CI, 12 to 36), and 23% (95% CI, 12 to 36), respectively
(P < .001). The 5-year probability of OS for recipients in CR1
receiving autologous HCT was 83% (95% CI, 69 to 91) versus
31% (95% CI, 19 to 44) in non-CR1 recipients. For recipients of
allogeneic HCT, 5-year OSwas 53% (95% CI, 34 to 69) for those
in CR1 versus 20% (95% CI, 12 to 30) in non-CR1 recipients
(P < .001). Patients in a second or subsequent CR receiving
autologous or allogeneic HCT had inferior 5-year OS rates,
53% (95% CI, 29 to 72) and 28% (95% CI, 15 to 43), respectively
(Table 4). OS at 5 years for those not in CR at HCT was
22% (95% CI, 10 to 36%) for autologous and 12% (95% CI, 4 to
25%) for allogeneic HCT cohorts (P < .001; Figures 2 and 3).fter HCT for BL by year of HCT.
Table 5
Causes of Death
Autologous
n (%)
HLA-Identical
Sibling n (%)
Unrelated/
Mismatched
Related n (%)
Number of deaths 56 54 37
Primary disease 44 (79) 39 (72) 22 (59)
GVHD 1 (2) 3 (6) 1 (3)
Pulmonary
syndrome
0 3 (6) 3 (8)
Infection 2 (4) 4 (7) 2 (5)
Organ failure 0 3 (6) 5 (14)
Other* 9 (16) 2 (4) 4 (11)
* Other includes new malignancy (n ¼ 3), hemorrhage (n ¼ 1), spongi-
form disorder brain (n ¼ 1), bilateral pneumonia ARDS (n ¼ 1), and not
speciﬁed (n ¼ 9).
L.V. Maramattom et al. / Biol Blood Marrow Transplant 19 (2013) 173e179178Survival of patients undergoing transplantation before and
after 2000 is shown in Figure 4.
Graft-versus-Host Disease
Cumulative incidences of aGVHD (at least grade II) in the
allogeneic cohort by day 100 were 35% (95% CI, 25 to 46) in
the HLA-identical sibling cohort and 53% (95% CI, 39 to 67) in
the unrelated/mismatched related cohort (P ¼ .04). Cumu-
lative incidences of aGVHD (at least grade III) in the alloge-
neic cohort by day 100 were 15% (95% CI, 8 to 24) in the
HLA-identical sibling cohort and 35% (95% CI, 23 to 49) in
the unrelated/mismatched related cohort (P ¼ .01). The
incidence of cGHVD at 5 years was 18% (95% CI, 10 to 28) in
the HLA-identical sibling cohort and 16% (95% CI, 7 to 28;
P ¼ .73) in the unrelated/mismatched related cohort
(Table 2). Seven HLA-identical sibling patients had limited
cGVHD, and four had extensive GVHD. All ﬁve unrelated
matched patients had extensive cGVHD.
Causes of Death
Most deathsd44 in the autologous cohort and 61 in the
allogeneic cohortdwere attributed to relapsed BL. Causes of
death are summarized in Table 5.
DISCUSSION
This analysis was designed to examine the changing role
of HCT in the era of modern chemotherapy for BL and to
deﬁne the outcomes after HCT. The trends identiﬁed in this
study conﬁrm the declining use of HCT in BL since the advent
of high-intensity chemotherapy regimens and the avail-
ability of rituximab. However, patients who relapse after
initial response to therapy have an extremely poor prognosis,
and there is a paucity of data to guide the treatment
approach of patients with relapsed or refractory BL.
A retrospective registry analysis of 117 adult patients who
underwent autologous HCT for BL included 47 patients with
relapsed or resistant disease [11]. OS rates at 3 years were
72%, 37%, and 7% for those undergoing transplantation in
CR1, those with chemotherapy-sensitive relapse, and those
with chemotherapy-resistant relapse, respectively. Our
analysis showed a 5-year OS rate for autologous HCT of 83%
for those in CR1, 53% for those in a subsequent CR, and 22%
for those not in CR. The allogeneic HCT cohort in our analysis
had 5-year survival rates of 53% for patients in CR1, 28% for
those in a subsequent CR, and 12% for those not in CR. The
allogeneic cohort was composed of patients who were
younger (<40 years) but had a higher proportion of
chemotherapy-resistant disease and more lines of priortherapy compared with the autologous cohort. Therefore, the
autologous and allogeneic cohorts are not directly compa-
rable. In reviewing the registry data, we could not ﬁnd
a reason by center for the choice of transplantation type.
A multivariate analysis was not performed because of the
major baseline imbalance between groups and the long time
period under study, during which time transplantation
practice changed substantially. The choice of allogeneic
versus autologous HCT is guided by factors such as chemo-
therapy sensitivity, donor availability, disease status before
autologous collection, and status of peripheral blood and
marrow involvement with BL. In the era of modern chemo-
therapy, there was a diminishing role for autologous HCT as
a consolidative measure in CR1, while allogeneic HCT seems
to be reserved for patients with advanced disease. Autolo-
gous HCT in the postrelapse setting resulted in a PFS rate of
44% at 5 years for those achieving a subsequent CR before
transplantation.
Unfortunately, the high NRM and high risk of relapse in
the ﬁrst year led to substantial early mortality after alloge-
neic HCT. A clear graft-versus-tumor effect cannot be deter-
mined from these data. The lack of relapse could represent
a graft-versus-tumor effect or could simply represent that
relapse is unlikely because patients at most risk died early.
Autologous HCT in CR1 in the era before modern intense
regimens for BLwereoffered seem tohaveequivalent survival
results compared with the reports for dose-intense modern
regimens such as CODOX-M (cyclophosphamide, vincristine,
doxorubicin, high-dose methotrexate)/IVAC (ifosfamide,
etoposode, high-dose cytarabine) and R-hyperCVAD (ritux-
imab, cyclophosphamide, vincristine, adriamycin, and
dexamethasone alternating with high-dose methotrexate
and cytarabine) [6,12]. With the CODOX-M/IVAC regimen,
the 2-year event-free survival rate was 50% to 60% in
high-risk patients [13,14]. These intense chemotherapy
regimens [6,12-14] are also associated with a lower NRM,
usually less than 5%, than those reported for allogeneic
HCT, but not necessarily autologous HCT. Notably in the
current analysis, patients receiving autologous HCT were
of high risk with a substantial proportion with extranodal
(70%) or central nervous system (12%) involvement. The
durability of beneﬁt from HCT demonstrated in this
analysis is longer than the follow-up duration in most
reports of contemporary chemotherapy regimens. The use
of autologous HCT after a shortened course of contem-
porary aggressive chemotherapy may remain an inter-
esting approach that could be tested in prospective trials.
Given these data, autologous HCT in CR1 is unlikely to
offer an additional advantage over current dose-intense
chemotherapy regimens. The declining use of HCT for BL in
the setting of CR1 is justiﬁed as the historical survival
outcomes from this study are not superior to reported
outcomes after current nontransplantation approaches,
particularly considering selection bias that might have
inﬂuenced decision making. However, HCT seems not to be
inferior given the long-term follow-up data. In patients with
advanced BL, autologous HCT may remain a salvage option
provided subsequent disease control is obtained with
second-line chemotherapy.
Allogeneic HCT was mostly performed in those with
higher risk/advanced BL and resulted in long-term PFS for
some patients, with relapses and mortality occurring mainly
within the ﬁrst year after HCT. HCT for BL will admittedly be
hard to study in trials given the rarity of the disease and the
good outcomes with upfront chemotherapy. Based on these
L.V. Maramattom et al. / Biol Blood Marrow Transplant 19 (2013) 173e179 179results, however, HCT should continue to be considered for
select patients.
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